MetaCap

ProKidney Corp. Class A Company Profile

NASDAQ: PROKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.04-0.02 (-1.89%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ProKidney at a glance

ProKidney Corp. Class A (NASDAQ: PROK) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Winston-Salem, NC. ProKidney is led by Dr. Bruce Culleton M.D. and employs about 231 people. The company's shares have traded publicly since 2021.

At a market capitalization of $415.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001850270, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does ProKidney do?

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Business description based on the company's public filings.

Company information

Legal name
ProKidney Corp. Class A
Ticker
NASDAQ: PROK
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Bruce Culleton M.D.
Employees
231
Headquarters
2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States
Phone
336 999 7019
IPO year
2021
Market cap
$415.21M
SEC CIK
0001850270
Latest annual report
10-K · Mar 18, 2026

Companies similar to ProKidney

PROK peer companies
CompanyPrice% ChgMarket capCompare
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs PROK
TVGNTevogen Inc.5.90-6.35%$405.20Mvs PROK
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs PROK
CADLCandel Therapeutics Inc.5.04-1.75%$395.37Mvs PROK
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs PROK
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs PROK
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs PROK
ALECAlector Inc.2.34+1.52%$347.63Mvs PROK

Related